{
    "clinical_study": {
        "@rank": "139437", 
        "acronym": "Challenge", 
        "arm_group": [
            {
                "arm_group_label": "GS-5806", 
                "arm_group_type": "Experimental", 
                "description": "GS-5806, powder for oral solution"
            }, 
            {
                "arm_group_label": "Sugar powder for oral solution in juice", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Sugar powder for oral solution"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to evaluate the antiviral effect of GS-5806 in healthy adults infected with a\n      strain of Respiratory Syncytial Virus."
        }, 
        "brief_title": "Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Respiratory Syncytial Virus Infections", 
        "condition_browse": {
            "mesh_term": [
                "Respiratory Syncytial Virus Infections", 
                "Virus Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male or female\n\n          -  Between 18 to 45 years old\n\n          -  Body Mass Index of 18 to 33 kg/m2\n\n        Exclusion Criteria:\n\n          -  Acute or chronic medical illness\n\n          -  Positive for Human Immunodeficiency Virus, Hepatitis B or C\n\n          -  Nose or nasopharynx abnormalities\n\n          -  Abnormal lung function"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01756482", 
            "org_study_id": "GS-US-218-0103"
        }, 
        "intervention": [
            {
                "arm_group_label": "GS-5806", 
                "description": "GS-5806, powder for oral solution", 
                "intervention_name": "GS-5806", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sugar powder for oral solution in juice", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Respiratory", 
            "Syncytial", 
            "Virus", 
            "Infections", 
            "RSV"
        ], 
        "lastchanged_date": "January 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "E12AX"
                }, 
                "name": "Retroscreen Virology"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 2a Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV-A Memphis 37b Strain)", 
        "overall_official": {
            "affiliation": "Retroscreen Virology", 
            "last_name": "Adeyi Adeyemi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: National Health Service", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Area under the curve for viral load as measured by qRT-PCR assay from the first viral load measurement post initial dose of GS-5806 or placebo through day 12.", 
            "measure": "Change in viral load measurements.", 
            "safety_issue": "Yes", 
            "time_frame": "Post initial dose of GS-5806/placebo to Day 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01756482"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Change of baseline symptoms post initial dose of GS-5806 or placebo through Day 12", 
            "measure": "Change of baseline symptoms", 
            "safety_issue": "Yes", 
            "time_frame": "Innoculation through Day 12"
        }, 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}